4th Quarter - Report

CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES

Firm
Client
Income
—
Expenses
$230,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Support legislation to reform Congressional Budget Office scoring of health care legislation

LobbyistCovered position, as disclosed
CHRISTOPHER CUNNINGHAM —
BRENTON J. FISK —
ANTHONY THEISSEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Oppose drug importation proposals Support diversity in clinical trial policy Support medical device change control plans legislation Oppose legislation that expands Medicare Drug Pricing Negotiation Program Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development (PASTEUR Act) Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs. Support legislation providing for e-labeling of medical devices

LobbyistCovered position, as disclosed
CHRISTOPHER CUNNINGHAM —
BRENTON J. FISK —
ANTHONY THEISSEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem Support capping Medicare beneficiary out of pocket costs Support value-based purchasing provision, but opposed line extensions and co-pay assistance provisions of CMS Medicaid VBP proposed rule Support legislation to expand and clarify the exclusion for orphan drugs under the Medicare Drug Price Negotiation Program Oppose CMS proposed changes to the Medicaid Drug Rebate Program (MDRP) to redefine how Medicaid Best Price is calculated Implement Medicare Drug Price Negotiation program in least harmful way - MFP at ceiling for innovative products, broad orphan drug exclusion, welcome patient and stakeholder input

LobbyistCovered position, as disclosed
CHRISTOPHER CUNNINGHAM —
BRENTON J. FISK —
ANTHONY THEISSEN —

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Support R&D and NOL tax incentives, Orphan Drug Tax Credits, repeal R&D tax amortization

LobbyistCovered position, as disclosed
CHRISTOPHER CUNNINGHAM —
BRENTON J. FISK —
ANTHONY THEISSEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

Support promulgation of TCET rule Support breakthrough device coverage bill Support legislation proposing coverage for multicancer screening

LobbyistCovered position, as disclosed
CHRISTOPHER CUNNINGHAM —
BRENTON J. FISK —
ANTHONY THEISSEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Copyright/Patent/Trademark CPT

Oppose "march-in" rights and "compulsory licensing" proposals Support transferable exclusivity extensions to incentivize novel antibiotic R&D

LobbyistCovered position, as disclosed
CHRISTOPHER CUNNINGHAM —
BRENTON J. FISK —
ANTHONY THEISSEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Trade (domestic/foreign) TRD

Oppose WTO TRIPS waiver for COVID diagnostics and therapeutics

LobbyistCovered position, as disclosed
CHRISTOPHER CUNNINGHAM —
BRENTON J. FISK —
ANTHONY THEISSEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.